Genedata said last week that Ono Pharmaceutical has licensed its Genedata Expressionist for Mass Spectrometry solution and that the Japanese firm would use the tool in its proteomics and metabolomics research efforts.

Ono develops drugs for cancer and cardiovascular diseases. Its research requires "accurate mass profiling analysis as well as powerful [multiple reaction monitoring] capabilities for effective quantitative analysis," a spokesperson for Ono's Tsukuba Research Institute said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.